SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Metrics to compare | SLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLSPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.1x | −0.3x | −0.5x | |
PEG Ratio | −0.07 | 0.01 | 0.00 | |
Price / Book | 13.4x | 2.0x | 2.6x | |
Price / LTM Sales | - | 11.2x | 2.9x | |
Upside (Analyst Target) | 328.6% | 198.8% | 57.1% | |
Fair Value Upside | Unlock | 11.4% | 9.0% | Unlock |